Habitat imaging of tumors enables high confidence sub-regional assessment of response to therapy
AuthorsTar, P. D.
Thacker, N. A.
Little, R. A.
Williams, K. J.
O'Connor, James P B
AffiliationDivision of Cancer Sciences, University of Manchester, Manchester M13 9PT, UK
MetadataShow full item record
AbstractImaging biomarkers are used in therapy development to identify and quantify therapeutic response. In oncology, use of MRI, PET and other imaging methods can be complicated by spatially complex and heterogeneous tumor micro-environments, non-Gaussian data and small sample sizes. Linear Poisson Modelling (LPM) enables analysis of complex data that is quantitative and can operate in small data domains. We performed experiments in 5 mouse models to evaluate the ability of LPM to identify responding tumor habitats across a range of radiation and targeted drug therapies. We tested if LPM could identify differential biological response rates. We calculated the theoretical sample size constraints for applying LPM to new data. We then performed a co-clinical trial using small data to test if LPM could detect multiple therapeutics with both improved power and reduced animal numbers compared to conventional t-test approaches. Our data showed that LPM greatly increased the amount of information extracted from diffusion-weighted imaging, compared to cohort t-tests. LPM distinguished biological response rates between Calu6 tumors treated with 3 different therapies and between Calu6 tumors and 4 other xenograft models treated with radiotherapy. A simulated co-clinical trial using real data detected high precision per-tumor treatment effects in as few as 3 mice per cohort, with p-values as low as 1 in 10,000. These findings provide a route to simultaneously improve the information derived from preclinical imaging while reducing and refining the use of animals in cancer research.
CitationTar PD, Thacker NA, Babur M, Lipowska-Bhalla G, Cheung S, Little RA, et al. Habitat Imaging of Tumors Enables High Confidence Sub-Regional Assessment of Response to Therapy. Vol. 14, Cancers. MDPI AG; 2022. p. 2159.
- A new method for the high-precision assessment of tumor changes in response to treatment.
- Authors: Tar PD, Thacker NA, Babur M, Watson Y, Cheung S, Little RA, Gieling RG, Williams KJ, O'Connor JPB
- Issue date: 2018 Aug 1
- Oxygen-enhanced MRI Is Feasible, Repeatable, and Detects Radiotherapy-induced Change in Hypoxia in Xenograft Models and in Patients with Non-small Cell Lung Cancer.
- Authors: Salem A, Little RA, Latif A, Featherstone AK, Babur M, Peset I, Cheung S, Watson Y, Tessyman V, Mistry H, Ashton G, Behan C, Matthews JC, Asselin MC, Bristow RG, Jackson A, Parker GJM, Faivre-Finn C, Williams KJ, O'Connor JPB
- Issue date: 2019 Jul 1
- A comparative assessment of preclinical chemotherapeutic response of tumors using quantitative non-Gaussian diffusion MRI.
- Authors: Xu J, Li K, Smith RA, Waterton JC, Zhao P, Ding Z, Does MD, Manning HC, Gore JC
- Issue date: 2017 Apr
- Prognostic value of MRI-derived masticator space involvement in IMRT-treated nasopharyngeal carcinoma patients.
- Authors: Xiao Y, Pan J, Chen Y, Lin S, Chen Y, Zong J, Fang Y, Guo Q, Chen B, Tang L
- Issue date: 2015 Sep 25
- PET and MRI Guided Irradiation of a Glioblastoma Rat Model Using a Micro-irradiator.
- Authors: Bolcaen J, Descamps B, Boterberg T, Vanhove C, Goethals I
- Issue date: 2017 Dec 28